Not yet reviewed — this article is pending editorial review by Lyrea.
3-Me-PCPy
3-Me-PCPy is an arylcyclohexylamine derivative1 with an uncommon dual pharmacological profile, producing both dissociative and stimulant effects. Unlike most substances in its class, it combines potent NMDA antagonism with triple monoamine reuptake inhibition affecting serotonin, dopamine, and noradrenaline. It also displays high affinity for sigma receptors. This broad spectrum of activity distinguishes it from related arylcyclohexylamines, contributing to its unusual combination of stimulant and dissociative properties.
Dosage & Duration
Subjective Effects
Formal human studies of 3-Me-PCPy subjective effects were not located. Available descriptions come from unverified community self-reports and should not be treated as clinical evidence. Across two reports, the experience was described as combining dissociation with stimulation, euphoria, dreaminess or dazed clarity, and some motor impairment. One intranasal author also described sociability, disinhibition, mild visual movement, numbness, dizziness, and a strong urge to redose; a rectal author described restlessness, sweating, and a dreamlike dissociative state. Product identity and purity were not independently confirmed, and these individual experiences cannot establish frequency or predict effects in other people.[cite:url-nervewing-594ac1][cite:url-bluelight-383d88]
Physical
Oral or extremity numbness and some motor impairment were described in the community reports.[cite:url-nervewing-594ac1][cite:url-bluelight-383d88] Dizziness was described by the intranasal author during onset.[cite:url-nervewing-594ac1] Warm, sweaty palms were described by the rectal author.[cite:url-bluelight-383d88]
Pharmacology
Pharmacodynamics
3-Me-PCPy acts as a potent NMDA receptor antagonist and a triple monoamine reuptake inhibitor, blocking the reuptake of serotonin, dopamine, and noradrenaline.2 It also functions as a high-affinity sigma receptor ligand with selectivity for the σ2 subtype.
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of 3-Me-PCPy and the metabolism of 3-Me-PCPy is unknown.
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Dissociatives (NMDA receptor antagonists), Other arylcyclohexylamines
Harm Potential
Addiction & Dependence
Psychological
One intranasal self-report described a strong urge to redose and use on multiple consecutive days.3 This is a community harm-reduction observation rather than clinical evidence: chemical identity, purity, co-exposures, and causality were not independently verified.34
Physical
No medically verified human evidence was located that can quantify physical dependence on 3-Me-PCPy. The peer-reviewed paper located for this review concerns synthesis and analytical identification rather than clinical toxicity, and absence of such reports does not establish safety.1
Toxicity
Psychosis Risk
The author of that intranasal self-report warned that repeated dosing might progress toward stimulated psychosis.3 No medically verified human evidence was located that can quantify psychosis risk for 3-Me-PCPy.1
Seizure Risk
Substance-specific seizure risk remains unknown; do not infer it from related arylcyclohexylamines. This is an evidence-gap statement, not a safety claim.1
History & Culture
3-Me-PCPy is a synthetic arylcyclohexylamine that has emerged as a novel psychoactive substance on the research chemical market.1 As a structural isomer of phencyclidine, it belongs to the broader family of dissociative compounds that have been systematically explored for…
Legality
By Country
References
Source Pages
Citations
- Jason Wallach, Giorgia De Paoli, Adeboye Adejare, & Simon D. Brandt. (2014). Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. Drug Testing and Analysis, 6(7–8), 633–50. https://doi.org/10.1002/dta.1468123456
- Jason Wallach, & Simon D. Brandt. (2018). New Psychoactive Substances. Handbook of Experimental Pharmacology, 252, 261–303. https://doi.org/10.1007/164_2018_124123456
- Personal experience report, July 2021. nervewing.blogspot.com (n.d.). https://nervewing.blogspot.com/2021/07/3-me-pcpy.html123456789101112131415
- Post in ‘The Small & Handy 3-Me-PCPy thread.’ Bluelight, June 5, 2021. bluelight.org (n.d.). https://www.bluelight.org/community/threads/the-small-handy-3-me-pcpy-thread.902963/post-1520431212345678910
- Nicky Döring, & Georg Wurth. (2022). Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act. Harm Reduction Journal, 19. https://doi.org/10.1186/s12954-022-00704-712
- Other Regulations/Medicine Legislation for Japan — UNODC Legal Substance System. (n.d.). https://www.unodc.org/LSS/Country/DetailsLegalSystem?code=ORML&country=JP1
- Psychoactive Substances Act 2016 (UK). (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-Me-PCPy article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.